Helsingborg

• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment Recruiting
  2025-524022-18-00 4 2026-05-22 Multiple myeloma
• Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody Recruiting
  2025-521416-19-00 4 2026-03-12 Recurrence of Clostridioides difficile Infection
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• COMeBAC- COMparison between Bensypenicillin And Cloxacillin treatment in PSSA Recruiting
  2023-506860-15-00 6 2024-06-11 Staphylococcus aureus bacteraemia
• Early Initiated Vasopressor Therapy in the Emergency Department - A Multi-center Randomized Controlled Trial (VASOSHOCK) Recruiting
  2023-504584-16-00 5 2023-12-08 Hypotension
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• Alternative antibiotics to multidrug-resistant UTIs Recruiting
  2024-513294-41-00 6 2023-04-17 Urinary tract infection and/or bacteremia caused by extended spectrum
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• OPTION – OutPatienT InductiON: Labour induction in an outpatient setting - a multicentre randomized controlled trial Recruiting
  2023-507164-39-00 6 2021-12-01 Induction of labour
• Optimized pharmacologic treatment for broken heart (takotsubo) syndrome Recruiting
  2022-501874-21-00 6 2020-12-15 Takotsubo syndrome
• A randomized controlled trial with Rituximab for Psychotic disorder in adults Ended recruitment
  2024-512408-20-00 4 2024-08-27 Schizophrenia spectrum disorder (SSD)
• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot … Ended recruitment
  2023-506668-15-00 5 2024-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended recruitment
  2023-505268-12-00 5 2024-02-09 Treatment-resistant depression
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas … Ended recruitment
  2023-503444-13-00 5 2023-03-29 Relapsed/refractory multiple myeloma
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial) Ended recruitment
  2023-504945-30-00 5 2021-03-16 Primary or recurrent non-muscle invasive bladder cancer with intermedi
• Evaluation of cortisone treatment in children suffering from acute facial nerve paralysis. Ended recruitment
  2024-513430-37-00 6 2019-06-01 Facial Nerve Palsy (Bells Palsy)
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation

Showing 1–24 of 26 trials